HK Stock Market Move | AKESO (09926) rose nearly 4%, launching the first head-to-head phase III clinical trial of the PD-L1 monoclonal antibody cardizenil.

AKESO (09926) rose by nearly 4%. As of the time of writing, it is up 3.95% at HK$63.2, with a trading volume of HK$275 million. On the news front, on September 23, according to the official website of CDE, AKESO has initiated a Phase III clinical trial of Cardinol monoclonal antibody (AK104), evaluating the efficacy of AK104 compared to Sunitinib monoclonal antibody in the consolidation treatment of locally advanced non-small cell lung cancer patients who have not experienced disease progression after synchronous/sequential radiotherapy and are not suitable for surgical resection, in a randomized controlled, double-blind, multicenter Phase III clinical study (first phase). It is worth mentioning that this is the first clinical study of Cardinol monoclonal antibody against PD-L1 monoclonal antibody. AK104 is a potential next-generation, first-in-class humanized IgG1 tetramer bispecific antibody drug independently developed by AKESO, aimed at preferentially binding to tumor-infiltrating lymphocytes rather than normal peripheral tissue lymphocytes, to provide better efficacy and safety. On June 29, 2022, Cardinol monoclonal antibody was first approved for use in recurrent or metastatic cervical cancer patients who had failed platinum chemotherapy, becoming the first domestic dual antibody drug.